2023 World Conference on Lung Cancer (Posters)-EP11.03. Characterizing Neurologic Immune-related Adverse Events Using Consensus Disease Definitions

Pdf Summary

This document discusses the characterization of neurologic immune-related adverse events (n-irAEs) using consensus disease definitions. n-irAEs can cause significant morbidity and mortality and can limit the use of immune checkpoint inhibitors (ICI). The lack of clear, standardized disease definitions can lead to misclassification of syndromes and difficulties in managing patients.<br /><br />The objectives of this study were to describe the classification structure of a Redcap registry for n-irAEs based on consensus disease definitions and to present data from the clinical application of these definitions to a single center cohort.<br /><br />The study included adult patients who received an ICI and were treated for suspected n-irAEs at Massachusetts General Hospital between January 2011 and December 2020. Additional patients were identified through the MGH Research Patient Data Registry who had a neurology encounter and met specific criteria. Chart review was performed to determine cancer type, treatment, and outcomes of toxicity.<br /><br />Neurologists with expertise in autoimmune disorders reviewed the assignment of neurologic diagnoses, probability of diagnosis, severity criteria, and supporting testing for each patient. The study found that neurologic irAEs typically present early in ICI treatment and peripheral nervous system irAEs are more common than central nervous system disorders. These toxicities are often severe and associated with high rates of ICI discontinuation.<br /><br />The successful application of consensus disease definitions for n-irAEs in a lung cancer population demonstrates the feasibility of using these definitions to characterize these important disorders. Accurate classification of neurologic irAEs is crucial for conducting prospective interventional trials and outcomes research for this under-studied class of toxicities.<br /><br />The study provides baseline demographic information about the neuro irAE patient cohort, including age, sex, race, cancer type, ECOG status, and history of neurologic autoimmune disease or other neurologic disorders. The outcomes of n-irAEs are also presented.<br /><br />Overall, this research highlights the importance of standardized disease definitions in the assessment and management of n-irAEs and provides insights into the characteristics and outcomes of these adverse events.

Asset Subtitle

Aliyah Pabani

Meta Tag

Speaker Aliyah Pabani

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

neurologic immune-related adverse events

consensus disease definitions

morbidity and mortality

immune checkpoint inhibitors

misclassification of syndromes

peripheral nervous system irAEs

central nervous system disorders

ICI discontinuation

lung cancer population

prospective interventional trials